Insider Analysis: The Insider and CEO & Chairman of Opko Health Inc. (NASDAQ:OPK), Phillip Frost, Acquired 5,600 Shares

November 29, 2016 - By Nellie Frank

Insider Analysis: The Insider and CEO & Chairman of Opko Health Inc. (NASDAQ:OPK), Phillip Frost, Acquired 5,600 Shares

Phillip Frost Insider Buy

Today, an insider trading trade was made. Phillip Frost, the CEO & Chairman and an insider of Opko Health Inc obtained precisely 5,600 shares of Opko Health Inc, worth exactly $59,411 U.S. Dollars, at $10.6 per share at the time of the trade. He also acquired 104,300 shares worth $995,782 USD in the last month. Now, Phillip Frost owns 183.53 million shares which make up around 33.58% of the company’s total market capitalization.

Insitutional Activity: The institutional sentiment increased to 1.8 in 2016 Q2. Its up 0.80, from 1 in 2016Q1. The ratio improved, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.

Private Advisor Limited Company has 0% invested in the company for 11,450 shares. Interocean Capital Limited Co holds 0.03% or 11,770 shares in its portfolio. Asset Advsrs Corporation last reported 0% of its portfolio in the stock. The New York-based Gabelli Secs Inc has invested 0.01% in Opko Health Inc. (NASDAQ:OPK). Commerzbank Aktiengesellschaft Fi holds 28,190 shares or 0% of its portfolio. Clal Limited has 2.25 million shares for 0.54% of their US portfolio. Geode Cap Mngmt Limited Liability holds 0.01% of its portfolio in Opko Health Inc. (NASDAQ:OPK) for 2.19M shares. Exchange Mngmt last reported 30 shares in the company. Employees Retirement Association Of Colorado last reported 0.01% of its portfolio in the stock. Hyman Charles D reported 18,119 shares or 0.03% of all its holdings. Moors Cabot reported 61,100 shares or 0.1% of all its holdings. Plante Moran Financial Advsrs Limited Liability Co last reported 1,279 shares in the company. Blackrock Advsr Ltd Com holds 0.01% of its portfolio in Opko Health Inc. (NASDAQ:OPK) for 817,637 shares. Hollencrest Securities Limited Liability Corporation owns 45,000 shares or 0.06% of their US portfolio. Moreover, Tiaa Cref Invest Limited Liability has 0.01% invested in Opko Health Inc. (NASDAQ:OPK) for 962,606 shares.

Insider Transactions: Since June 1, 2016, the stock had 64 insider purchases, and 0 sales for $5.60 million net activity. On Friday, September 2 the insider FROST PHILLIP MD ET AL bought $92,800.

The stock decreased 1.94% or $0.21 during the last trading session, hitting $10.62. Opko Health Inc. (NASDAQ:OPK) has declined 5.35% since April 26, 2016 and is downtrending. It has underperformed by 10.61% the S&P500.

OPKO Health, Inc. is a healthcare company. The company has a market cap of $5.99 billion. The Firm operates through two divisions: diagnostics and pharmaceutical. It currently has negative earnings. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations.

According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”

Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on March, 6. After $-0.03 actual EPS reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts 66.67% negative EPS growth.

Another recent and important Opko Health Inc. (NASDAQ:OPK) news was published by Seekingalpha.com which published an article titled: “OPKO Health: Significant Growth Potential From FDA Approval” on November 10, 2016.

OPK Company Profile

OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>